Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamfetamine Sulfate in Adults With ADHD and Moderate to Severe Depression
NCT06967857Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adenosine-5′-monophosphate in attention deficit hyperactivity disorder (ADHD) and major depressive disorder (MDD) (3 arms). Primary endpoint: Incidence of adverse events at 17 weeks. Started May 2025; status: recruiting.
02
Drugs
adenosine-5′-monophosphate
03
Conditions
attention deficit hyperactivity disorder (ADHD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06967857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967857.